According to a new study, a weekly dose of a medicine newly approved by the US Food and Drug Administration to treat type 2 Diabetes may also help persons without Diabetes lose weight. Tirzepatide, marketed under the trade name Mounjaro, was tested in non-diabetic persons at three different doses: 5, 10, and 15 mg. Participants with obesity or overweight who received the 5-milligram dosage lost an average of 35 pounds, those who received the 10-milligram dose lost an average of 49 pounds, and those who received the 15-milligram dose lost an average of 52 pounds.
Over the course of the 72-week double-blinded, randomized clinical trial, persons without Diabetes lost an average of 15% to 20.9 percent of their initial body weight, according to the findings, which were published Saturday in The New England Journal of Medicine. Participants who received a placebo dropped an average of 2.4 percent to 3.1 percent of their body weight